PR Newswire
AUSTIN, Texas , April 6, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as follows:
Conference: 21 st Annual Needham Virtual Healthcare Conference, April 11-14, 2022
Presentation Date/Time: Wednesday, April 13 at 9:30 a.m. EDT
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and CEO
Webcast: https://wsw.com/webcast/needham117/agle/2213747
To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company's website. A replay of Company webcasts is archived on the website for 30 days following presentations.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. In December 2021 , Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency. Pegzilarginase has received both Rare Pediatric Disease and Breakthrough Therapy Designations. Aeglea also has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com .
SOURCE Aeglea BioTherapeutics, Inc.